oligonucleotide microarray based microarray platform Search Results


oligonucleotide microarray platform  (CombiMatrix)
90
CombiMatrix oligonucleotide microarray platform
Oligonucleotide Microarray Platform, supplied by CombiMatrix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oligonucleotide microarray platform/product/CombiMatrix
Average 90 stars, based on 1 article reviews
oligonucleotide microarray platform - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
microarray analysis based on slides printed with oligonucleotides designed to zebra fish expressed sequence tags  (Compugen Inc)
90
Compugen Inc microarray analysis based on slides printed with oligonucleotides designed to zebra fish expressed sequence tags
Microarray Analysis Based On Slides Printed With Oligonucleotides Designed To Zebra Fish Expressed Sequence Tags, supplied by Compugen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microarray analysis based on slides printed with oligonucleotides designed to zebra fish expressed sequence tags/product/Compugen Inc
Average 90 stars, based on 1 article reviews
microarray analysis based on slides printed with oligonucleotides designed to zebra fish expressed sequence tags - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
abi high-density oligonucleotide microarray platform  (Celera)
90
Celera abi high-density oligonucleotide microarray platform
Abi High Density Oligonucleotide Microarray Platform, supplied by Celera, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abi high-density oligonucleotide microarray platform/product/Celera
Average 90 stars, based on 1 article reviews
abi high-density oligonucleotide microarray platform - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
custom oligonucleotide-based dna microarray  (Lallemand inc)
90
Lallemand inc custom oligonucleotide-based dna microarray
Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a <t>DNA</t> <t>microarray.</t> A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.
Custom Oligonucleotide Based Dna Microarray, supplied by Lallemand inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/custom oligonucleotide-based dna microarray/product/Lallemand inc
Average 90 stars, based on 1 article reviews
custom oligonucleotide-based dna microarray - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
oligonucleotide microarray-based mirna detection platform  (CapitalBio Corporation)
90
CapitalBio Corporation oligonucleotide microarray-based mirna detection platform
Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a <t>DNA</t> <t>microarray.</t> A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.
Oligonucleotide Microarray Based Mirna Detection Platform, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oligonucleotide microarray-based mirna detection platform/product/CapitalBio Corporation
Average 90 stars, based on 1 article reviews
oligonucleotide microarray-based mirna detection platform - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
genomic microarray 105,000 dna oligonucleotides probes v3.1 platform  (GeneDx Inc)
90
GeneDx Inc genomic microarray 105,000 dna oligonucleotides probes v3.1 platform
Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a <t>DNA</t> <t>microarray.</t> A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.
Genomic Microarray 105,000 Dna Oligonucleotides Probes V3.1 Platform, supplied by GeneDx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genomic microarray 105,000 dna oligonucleotides probes v3.1 platform/product/GeneDx Inc
Average 90 stars, based on 1 article reviews
genomic microarray 105,000 dna oligonucleotides probes v3.1 platform - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
oligonucleotide-based microarray specific m. gallisepticum strain rlow  (MWG-Biotech ag)
90
MWG-Biotech ag oligonucleotide-based microarray specific m. gallisepticum strain rlow
Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a <t>DNA</t> <t>microarray.</t> A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.
Oligonucleotide Based Microarray Specific M. Gallisepticum Strain Rlow, supplied by MWG-Biotech ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oligonucleotide-based microarray specific m. gallisepticum strain rlow/product/MWG-Biotech ag
Average 90 stars, based on 1 article reviews
oligonucleotide-based microarray specific m. gallisepticum strain rlow - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
mouse exonic evidence-based oligonucleotide microarrays  (Ocean Ridge Biosciences)
90
Ocean Ridge Biosciences mouse exonic evidence-based oligonucleotide microarrays
Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a <t>DNA</t> <t>microarray.</t> A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.
Mouse Exonic Evidence Based Oligonucleotide Microarrays, supplied by Ocean Ridge Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse exonic evidence-based oligonucleotide microarrays/product/Ocean Ridge Biosciences
Average 90 stars, based on 1 article reviews
mouse exonic evidence-based oligonucleotide microarrays - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
oligonucleotide-based microarray specific m. gallisepticum strain r low  (MWG-Biotech ag)
90
MWG-Biotech ag oligonucleotide-based microarray specific m. gallisepticum strain r low
Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a <t>DNA</t> <t>microarray.</t> A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.
Oligonucleotide Based Microarray Specific M. Gallisepticum Strain R Low, supplied by MWG-Biotech ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oligonucleotide-based microarray specific m. gallisepticum strain r low/product/MWG-Biotech ag
Average 90 stars, based on 1 article reviews
oligonucleotide-based microarray specific m. gallisepticum strain r low - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
oligonucleotide microarray platforms cytochip oligo 8 × 60 k  (BlueGnome Limited)
90
BlueGnome Limited oligonucleotide microarray platforms cytochip oligo 8 × 60 k
Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a <t>DNA</t> <t>microarray.</t> A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.
Oligonucleotide Microarray Platforms Cytochip Oligo 8 × 60 K, supplied by BlueGnome Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oligonucleotide microarray platforms cytochip oligo 8 × 60 k/product/BlueGnome Limited
Average 90 stars, based on 1 article reviews
oligonucleotide microarray platforms cytochip oligo 8 × 60 k - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
4 × 180 k cytosureisca v2 oligonucleotide microarray platform  (Oxford Gene Technology)
90
Oxford Gene Technology 4 × 180 k cytosureisca v2 oligonucleotide microarray platform
Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal <t>microarray</t> analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included
4 × 180 K Cytosureisca V2 Oligonucleotide Microarray Platform, supplied by Oxford Gene Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4 × 180 k cytosureisca v2 oligonucleotide microarray platform/product/Oxford Gene Technology
Average 90 stars, based on 1 article reviews
4 × 180 k cytosureisca v2 oligonucleotide microarray platform - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
human exonic evidence-based 70-mer oligonucleotide chips  (Microarrays Inc)
90
Microarrays Inc human exonic evidence-based 70-mer oligonucleotide chips
Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal <t>microarray</t> analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included
Human Exonic Evidence Based 70 Mer Oligonucleotide Chips, supplied by Microarrays Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human exonic evidence-based 70-mer oligonucleotide chips/product/Microarrays Inc
Average 90 stars, based on 1 article reviews
human exonic evidence-based 70-mer oligonucleotide chips - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a DNA microarray. A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

doi: 10.1093/cid/ciw185

Figure Lengend Snippet: Pearson similarity index of donors over time and recurrent Clostridium difficile infection (RCDI) patients to donors. Samples were analyzed using a DNA microarray. A , Donors retained a high degree of similarity to their own samples over their donation time period. Donor 1 = 18 months; Donor 2 = 12 months; Donor 3 = 7 months ( B ) Percent similarity of the single fecal microbiota transplantation (FMT) recipient samples at those time points (1 = 1–4 weeks; 2 = 8–52 weeks post FMT [PFT]) to their respective donor. Following FMT, the similarity of the RCDI patients increased to more closely resemble the donors; **** P -value <.0001 calculated using paired t -test; *** P -value =.0005 calculated using Mann–Whitney test. C , Percent similarity of the repeated FMT recipient samples at those time points to the respective donor of the most recent FMT (PFT1: 1–2 weeks; PFT2: 3–28 weeks); * P -value <.05; ** P -value <.005 both calculated using Mann–Whitney test. Whiskers denote mean with the standard deviation. Abbreviation: BFT, before FMT.

Article Snippet: DNA was extracted and analyzed on a custom oligonucleotide-based DNA microarray containing 370 probes targeting 354 ABR genes (Lallemand Health Solutions, Montreal, Canada).

Techniques: Infection, Microarray, Transplantation Assay, MANN-WHITNEY, Standard Deviation

Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal microarray analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included

Journal: European Journal of Human Genetics

Article Title: Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray

doi: 10.1038/s41431-017-0020-3

Figure Lengend Snippet: Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal microarray analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included

Article Snippet: CMA was undertaken using the 4 × 180 K CytoSureISCA v2 oligonucleotide microarray platform (Oxford Gene Technology, Oxford, UK), the standard diagnostic service offered by SickKids Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratory.

Techniques: Diagnostic Assay, Microarray, Sequencing, Activity Assay, Biomarker Discovery